Tirzepatide (Mounjaro / Zepbound): What the Research Shows

The dual GLP-1 and GIP agonist that outperformed semaglutide head-to-head — Eli Lilly’s bid for the weight loss crown

Tirzepatide is the first approved dual GLP-1/GIP receptor agonist — a compound that simultaneously activates two incretin hormone receptors through a single molecule. Eli Lilly’s “twincretin” approach produced weight loss outcomes that exceeded anything previously achieved with pharmacological obesity treatment: a mean 22.5% body weight reduction at the 15 mg dose in SURMOUNT-1, outperforming semaglutide’s ~15% and approaching the weight loss seen with bariatric surgery in some patients. When SURMOUNT-5 directly compared tirzepatide to semaglutide head-to-head in 2025, tirzepatide won at both doses tested.

Tirzepatide’s superiority is not simply a matter of adding a second receptor. GLP-1 and GIP interact synergistically at central appetite circuits, adipose tissue lipolysis pathways, and pancreatic beta cell function in ways that produce an effect greater than the sum of either receptor agonized alone. The precise mechanisms underlying this synergy are an active area of research — the clinical data is ahead of the mechanistic understanding in some respects.

Approved for type 2 diabetes in 2022 (Mounjaro) and obesity in 2023 (Zepbound), tirzepatide has become one of the fastest-adopted new medications in recent pharmaceutical history. The 2024 approval for obstructive sleep apnea — the first pharmacological treatment for OSA — added another dimension to the clinical picture. The weight loss magnitude and the breadth of metabolic and comorbidity benefit make tirzepatide the current clinical standard for obesity pharmacotherapy pending Phase III data from triple agonists.

Quick Facts

---

What Is Tirzepatide?

Tirzepatide is a 39-amino acid synthetic peptide engineered to act as a balanced agonist at both GLP-1R and GIPR. The compound’s backbone derives from the GIP sequence, modified to enable GLP-1R binding. A C20 fatty diacid chain attached via a linker to the peptide backbone enables albumin binding, extending the half-life to approximately 5 days — sufficient for once-weekly dosing. The two receptor targets are activated with approximately equal affinity in cellular assays, though the in vivo pharmacodynamic balance between GLP-1R and GIPR effects at different tissues is more complex.

GIP (glucose-dependent insulinotropic polypeptide) is secreted by small intestinal K-cells in response to nutrient ingestion and is the dominant incretin hormone in terms of volume of secretion. Like GLP-1, it stimulates glucose-dependent insulin release from pancreatic beta cells. Unlike GLP-1, GIP does not suppress glucagon or slow gastric emptying to the same degree — and, critically, GIP promotes adipogenesis rather than opposing it in states of energy surplus. This apparent paradox — why would agonizing a pro-adipogenic receptor help with weight loss? — was a key scientific question in tirzepatide’s development, now partially answered by the observation that GIPR activation in the context of GLP-1R co-activation has different downstream effects than GIPR activation alone.

---

Origins and Development

Eli Lilly’s development of tirzepatide built on their experience with GIP-based compounds and on the emerging understanding of incretin biology from GLP-1 receptor agonist development. The rationale for dual GLP-1/GIP agonism was partly mechanistic (complementary incretin pathways) and partly observational: patients who had undergone Roux-en-Y gastric bypass surgery showed elevated postprandial GIP as well as GLP-1, and bypass surgery produces weight loss and metabolic outcomes that exceed GLP-1 agonism alone.

Phase I studies established tirzepatide’s pharmacokinetics and initial safety. The SURPASS Phase III program for type 2 diabetes enrolled over 6,000 patients across multiple trials, establishing tirzepatide’s glycemic efficacy against placebo, semaglutide, insulin analogs, and other comparators. The SURMOUNT program for obesity enrolled over 5,000 participants, with SURMOUNT-1 producing the landmark weight loss data. FDA approved Mounjaro for T2D in May 2022 and Zepbound for obesity in November 2023.

---

Mechanism of Action

GLP-1R Agonism

Tirzepatide’s GLP-1R activity mirrors semaglutide’s: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, gastric emptying delay, and central appetite suppression via hypothalamic and brainstem GLP-1R. These effects are well-characterized from the broader GLP-1 agonist class.

GIPR Agonism

GIPR agonism adds several effects beyond GLP-1R action. In pancreatic beta cells, GIPR co-activation produces synergistic insulin release — greater than either receptor alone. In adipose tissue, GIPR agonism in the context of caloric restriction appears to switch adipocyte biology toward lipolysis rather than storage, contributing to the greater fat mass reduction seen with tirzepatide versus semaglutide. In the brain, GIPR is expressed on neurons that overlap with GLP-1R-expressing appetite-regulatory circuits; the interaction produces enhanced anorectic signaling relative to GLP-1R agonism alone.

Synergy — More Than Additive

The clinical data consistently shows tirzepatide outperforming GLP-1 agonists alone by a margin that exceeds what would be predicted from additive pharmacology. The synergy reflects the biology of the GLP-1/GIP axis: these two hormones evolved together as complementary signals of nutrient ingestion, and their receptors share downstream signaling elements that interact in complex ways. GIP may also sensitize GLP-1R to agonism — making the GLP-1R component of tirzepatide more effective than it would be without concurrent GIPR activation.

---

Approved Indications

---

Key Research Areas and Studies

SURMOUNT-1 — The Landmark

SURMOUNT-1 (N=2539, no T2D) enrolled adults with obesity (BMI ≥30) or overweight with comorbidities and randomized to tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks. Mean weight loss: 15.0%, 19.5%, and 22.5% for the three doses vs. 2.5% placebo. 37.0% of participants on the 15 mg dose achieved ≥25% weight loss. These results represented the largest weight loss in any Phase III obesity medication trial and approached surgical outcomes for some patients.

SURMOUNT-OSA — Sleep Apnea

Two parallel trials in adults with moderate-to-severe OSA and obesity (one with CPAP/PAP therapy, one without). Tirzepatide 10–15 mg weekly reduced AHI by 55% (with PAP) and 63% (without PAP) versus ~5% placebo at 52 weeks. 42–51% of participants achieved OSA remission (AHI <5). This is a mechanistically significant finding with implications beyond obesity — it demonstrates that metabolic pharmacotherapy can achieve disease remission in a condition previously treated only with mechanical support.

SURMOUNT-5 — Head-to-Head vs. Semaglutide

The first large, randomized head-to-head trial comparing tirzepatide and semaglutide for obesity. Published 2025. Tirzepatide 10 mg and 15 mg weekly versus semaglutide 2.4 mg weekly. Tirzepatide produced significantly more weight loss at both doses. The magnitude of difference (approximately 5–7 percentage points additional weight loss for tirzepatide over semaglutide) is clinically meaningful and establishes tirzepatide as the superior weight loss agent in the incretin class.

---

Common Claims versus Current Evidence

---

Safety, Risks, and Limitations

Gastrointestinal Adverse Effects

Same class as semaglutide: nausea, vomiting, diarrhea, and constipation are the most common adverse effects, most pronounced during dose escalation. In SURMOUNT-1, nausea occurred in ~32% of participants on 15 mg vs. ~9% placebo. Discontinuation for GI events occurred in ~4–5%. The slower titration schedule (4 weeks at each dose step) substantially mitigates GI burden.

Pancreatitis and Thyroid C-Cell Risk

Same class warnings as all GLP-1R agonists: pancreatitis risk and thyroid C-cell tumor risk (black box warning based on rodent data; human relevance uncertain). Contraindicated in patients with MEN2 or personal/family history of medullary thyroid carcinoma.

Hypoglycemia

When used without insulin or sulfonylureas, hypoglycemia risk is low due to the glucose-dependent mechanism of insulin secretion. In patients on insulin or sulfonylureas, dose reduction of the concomitant medication is typically required when initiating tirzepatide.

Muscle Mass and Body Composition

The exceptional weight loss magnitude with tirzepatide raises proportionally larger concerns about lean mass loss. Trials measuring body composition show lean mass losses consistent with high total weight loss — managing this with resistance exercise and protein intake is important, particularly in older adults.

---

Regulatory and Legal Status

Tirzepatide is a prescription medication in the United States and all major jurisdictions. Mounjaro for T2D, Zepbound for obesity and OSA. Not WADA prohibited. Access and cost patterns are similar to semaglutide; compounded tirzepatide has also emerged during supply constraints, with the same quality and regulatory caveats applying. The FDA shortage resolution timeline for tirzepatide has been distinct from semaglutide.

---

Approved Clinical Dosing

---

Frequently Asked Questions

Is Mounjaro the same as Zepbound?

Same active ingredient and injection device, different approved indications and pricing. Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity and sleep apnea. The approved dose ranges overlap substantially. Some patients use Mounjaro off-label for weight loss when covered by diabetes insurance pathways; this is prescriber-discretion off-label use, not an approved indication.

How does tirzepatide compare to semaglutide?

Tirzepatide produces approximately 5–7 percentage points more weight loss than semaglutide 2.4 mg weekly in direct head-to-head comparison (SURMOUNT-5). Both are approved GLP-1R agonists. Tirzepatide additionally activates GIPR, which appears to confer the additional weight loss benefit. For T2D, tirzepatide also outperformed semaglutide 1 mg in SURPASS-2. In patients who have been on semaglutide without adequate response, switching to tirzepatide is an evidence-supported option.

Will retatrutide replace tirzepatide?

Retatrutide (triple GLP-1/GIP/glucagon agonist) showed ~24% weight loss in Phase II — modestly above tirzepatide’s best Phase III data. Phase III results (TRIUMPH) are awaited. If Phase III confirms Phase II efficacy and the safety profile is acceptable, retatrutide may become the next standard — but the transition from Phase II to Phase III has historically been where promising weight loss data is tested at scale. Tirzepatide’s Phase III and real-world data provides a very strong comparator benchmark.

---

Related Compounds

---

Summary and Key Takeaways

• Tirzepatide is the first approved dual GLP-1/GIP receptor agonist, producing ~22% mean weight loss at the 15 mg dose in SURMOUNT-1 — the largest Phase III obesity pharmacotherapy weight loss data at time of approval.
• Outperforms semaglutide in head-to-head comparison (SURMOUNT-5, 2025); currently the superior weight loss agent in the incretin class.
• FDA-approved for T2D (Mounjaro), obesity (Zepbound), and sleep apnea (Zepbound, 2024) — the first pharmacological OSA treatment.
• GI adverse effects are common during titration; slow 4-week step escalation substantially reduces burden.
• GIPR agonism adds to GLP-1R effects through synergistic mechanisms at central appetite circuits, adipose tissue, and pancreatic beta cells.
• Not WADA prohibited. Prescription medication — prescriber oversight required.

---

Selected References

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. (SURMOUNT-1)
2. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15. (SURPASS-2)
3. Wharton S, et al. Tirzepatide for OSA in obesity. N Engl J Med. 2024;391(13):1193–205. (SURMOUNT-OSA)
4. SURMOUNT-5 investigators. Tirzepatide vs. semaglutide for obesity: SURMOUNT-5. N Engl J Med. 2025. [Published 2025]
5. Zepbound and Mounjaro prescribing information. Eli Lilly. 2024.

---

Further Reading

• Semaglutide article — peptidings.com/peptides/semaglutide/
• Semaglutide vs. Tirzepatide comparison — peptidings.com/peptides/semaglutide-vs-tirzepatide/
• Retatrutide article — peptidings.com/peptides/retatrutide/
• Weight Loss & Metabolic Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/

---